![](https://investorshub.advfn.com/uicon/25583.png?cb=1468325215)
Thursday, November 20, 2014 1:31:27 PM
Hello Dr. Seymour,
As you have likely seen the iHubbers are going somewhat crazy over a few things in the 10Q.
Can you address:
Why did the company state on several occasions that the materials for Tox would be produced at the existing facility, and now the 10Q says you need to finish the new facility in order to deliver sufficient quantities of Flucide for Tox completion?
Why did the company state that the work on Ebolacide2 would not impact the Flucide timeline for Tox (unless there were positive results from the Ebolacide2 testing) , and the 10Q says Flucide will be slowed due to Ebolacide2 development?
What is the current timeline for Flucide...approx when will Tox be completed, when will clinicals begin?
You said that Flucide Tox materials were delayed by the need to divert materials to other labs, why has there been no news from any of these other labs?
The SwingTrade Portfolio is up 42.1% YTD through 8/8/2014, 83.5% in 2013, and 537.4% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105141243
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM